Tildrakizumab for psoriatic arthritis in adults

Tildrakizumab is in clinical development for the treatment of active psoriatic arthritis (PsA). PsA is a long-term condition that causes stiff, inflamed, or painful joints, especially in the hands and feet. PsA is caused when the immune system attacks healthy tissue in the body. People with PsA can have symptoms such as swollen toes or fingers, damaged nails, and joint pain. If not treated, PsA can lead to bone and tissue damage. There is an unmet need for therapies that address all the different types of PsA and that can improve patient quality of life.